{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T19:50:09Z","timestamp":1792007409412,"version":"4.4.0"},"reference-count":78,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>There is still an unmet need for the treatment of high-risk hematological malignancies. To date, allogeneic stem cell transplantation remains the only chance of cure. Most patients suffering from high-risk hematological malignancies are of an older age and often present with comorbidities. Moreover, patients achieving remission often suffer from early relapse. Amongst the different treatment options, sequential conditioning has yet to prove its value against other conditioning regimens. Sequential conditioning relies on a short course of intensive chemotherapy that is quickly followed by immunosuppressive conditioning before allogeneic stem cell transplantation. Here, we will try to determine which patients can benefit from sequential conditioning. Amongst the different sequential regimens, we will also try to assess if one regimen is better than all the others. Despite the several studies conducted on sequential conditioning, very few are prospective work and head-to-head comparisons are almost inexistant. Sequential conditioning also relies on the use of prophylactic donor lymphocyte infusion post-transplantation. Hence, limiting non-relapse complications is of primary importance to the allow administration of post-transplant treatment. In the era of new targeting therapies, is there still a place for sequential conditioning? Can patients benefit from an association of new therapeutic agents and sequential conditioning?<\/jats:p>","DOI":"10.3390\/curroncol32040196","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T03:35:28Z","timestamp":1743132928000},"page":"196","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Is There (Still) a Place for Sequential Conditioning?"],"prefix":"10.3390","volume":"32","author":[{"given":"Boris","family":"Bours","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Oncology, Geneva University Hospitals, 1205 Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7502-5454","authenticated-orcid":false,"given":"Stavroula","family":"Masouridi-Levrat","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Oncology, Geneva University Hospitals, 1205 Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/ajh.26601","article-title":"Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia","volume":"97","author":"DiNardo","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1365-2141.2011.08869.x","article-title":"Primary refractory acute myeloid leukaemia\u2014In search of better definitions and therapies","volume":"155","author":"Ravandi","year":"2011","journal-title":"Br. J. Haematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3730","DOI":"10.1200\/JCO.2010.28.8852","article-title":"Hematopoietic Stem-Cell Transplantation for Acute Leukemia in Relapse or Primary Induction Failure","volume":"28","author":"Duval","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S2352-3026(15)00146-5","article-title":"Outcomes after use of two standard ablative regimens in patients with refractory acute myeloid leukaemia: A retrospective, multicentre, registry analysis","volume":"2","author":"Nagler","year":"2015","journal-title":"Lancet Haematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jtct.2021.02.031","article-title":"Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial","volume":"27","author":"Scott","year":"2021","journal-title":"Transplant. Cell Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","article-title":"Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes","volume":"35","author":"Scott","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/sj.leu.2404037","article-title":"Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: The role of dose intensity","volume":"20","author":"Shimoni","year":"2006","journal-title":"Leukemia"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jcyt.2024.11.012","article-title":"Allogeneic hematopoietic stem cell transplantation using reduced intensity conditioning regimen for patients with acute myeloid leukemia not in complete remission","volume":"27","author":"Shimomura","year":"2025","journal-title":"Cytotherapy"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1007\/s00432-021-03836-8","article-title":"Combination of treosulfan, fludarabine and cytarabine as conditioning in patients with acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasms","volume":"148","author":"Frietsch","year":"2022","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jtct.2022.10.027","article-title":"Clofarabine and Busulfan Myeloablative Conditioning in Allogeneic Hematopoietic Cell Transplantation for Patients with Active Myeloid Malignancies","volume":"29","author":"Connor","year":"2023","journal-title":"Transplant. Cell. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.bbmt.2005.06.004","article-title":"High Disease Burden Is Associated with Poor Outcomes for Patients with Acute Myeloid Leukemia Not in Remission Who Undergo Unrelated Donor Cell Transplantation","volume":"12","author":"Blum","year":"2006","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00432-015-2050-y","article-title":"Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation","volume":"142","author":"Pfrepper","year":"2016","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/s41409-023-01961-1","article-title":"Impact of disease burden on clinical outcomes of AML patients receiving allogeneic hematopoietic cell transplantation: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"58","author":"Dalle","year":"2023","journal-title":"Bone Marrow Transplant."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/sj.bmt.1702690","article-title":"Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: A retrospective study of 379 patients reported to the Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Moelle (SFGM)","volume":"26","author":"Michallet","year":"2000","journal-title":"Bone Marrow Transplant."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3324\/haematol.2016.159343","article-title":"Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: A meta-analysis","volume":"102","author":"Buckley","year":"2017","journal-title":"Haematologica"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1200\/JCO.2010.31.8121","article-title":"Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia","volume":"29","author":"Walter","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1200\/JCO.2005.07.061","article-title":"Sequential Regimen of Chemotherapy, Reduced-Intensity Conditioning for Allogeneic Stem-Cell Transplantation, and Prophylactic Donor Lymphocyte Transfusion in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome","volume":"23","author":"Schmid","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1007\/s00277-020-04131-1","article-title":"The FLAMSA concept\u2014Past and future","volume":"99","author":"Kolb","year":"2020","journal-title":"Ann. Hematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"17","DOI":"10.7326\/0003-4819-93-1-17","article-title":"4\u2032-(9-Acridinylamino) methanesulfon-m-anisidide (AMSA): A new drug effective in the treatment of adult acute leukemia","volume":"93","author":"Legha","year":"1980","journal-title":"Ann. Intern. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1200\/JCO.20.02308","article-title":"Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia","volume":"39","author":"Craddock","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41409-018-0288-0","article-title":"Comparison of FLAMSA-based reduced intensity conditioning with treosulfan\/fludarabine conditioning for patients with acute myeloid leukemia: An ALWP\/EBMT analysis","volume":"54","author":"Sheth","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1007\/s00277-022-04822-x","article-title":"Conditioning with fludarabine and treosulfan compared to FLAMSA-RIC in allogeneic stem cell transplantation for myeloid malignancies: A retrospective single-center analysis","volume":"101","author":"Braitsch","year":"2022","journal-title":"Ann. Hematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3324\/haematol.2016.150326","article-title":"Sequential regimen of clofarabine, cytosine arabinoside and reduced-intensity conditioned transplantation for primary refractory acute myeloid leukemia","volume":"102","author":"Mohty","year":"2017","journal-title":"Haematologica"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1007\/s00277-020-04074-7","article-title":"Sequential allogeneic hematopoietic stem cell transplantation for active refractory\/relapsed myeloid malignancies: Results of a reduced-intensity conditioning preceded by clofarabine and cytosine arabinoside, a retrospective study on behalf of the SFGM-TC","volume":"99","author":"Labopin","year":"2020","journal-title":"Ann. Hematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.bbmt.2018.01.005","article-title":"Sequential Conditioning with Thiotepa in T Cell- Replete Hematopoietic Stem Cell Transplantation for the Treatment of Refractory Hematologic Malignancies: Comparison with Matched Related, Haplo-Mismatched, and Unrelated Donors","volume":"24","author":"Chantepie","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/bmt.2014.328","article-title":"Sequential therapy combining clofarabine and T-cell-replete HLA-haploidentical haematopoietic SCT is feasible and shows efficacy in the treatment of refractory or relapsed aggressive lymphoma","volume":"50","author":"Zoellner","year":"2015","journal-title":"Bone Marrow Transplant."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1007\/s00277-013-1862-6","article-title":"Feasibility of clofarabine cytoreduction followed by haploidentical hematopoietic stem cell transplantation in patients with relapsed or refractory advanced acute leukemia","volume":"92","author":"Tischer","year":"2013","journal-title":"Ann. Hematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1002\/ajh.25281","article-title":"Sequential HLA-haploidentical transplantation utilizing post-transplantation cyclophosphamide for GvHD prophylaxis in high-risk and relapsed\/refractory AML\/MDS","volume":"93","author":"Fraccaroli","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s00277-019-03593-2","article-title":"Comparable outcome after haploidentical and HLA-matched allogeneic stem cell transplantation for high-risk acute myeloid leukemia following sequential conditioning-a matched pair analysis","volume":"98","author":"Doppelhammer","year":"2019","journal-title":"Ann. Hematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jtct.2021.07.018","article-title":"FLAMSA-Busulfan-Melphalan as a Sequential Conditioning Regimen in HLA-Matched or Haploidentical Hematopoietic Stem Cell Transplantation for High-Risk Myeloid Diseases","volume":"27","author":"Jondreville","year":"2021","journal-title":"Transplant. Cell. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/s41409-018-0283-5","article-title":"Clinical outcome of FLAG-IDA chemotherapy sequential with Flu\u2013Bu3 conditioning regimen in patients with refractory AML: A parallel study from Shanghai Institute of Hematology and Institut Paoli-Calmettes","volume":"54","author":"Wang","year":"2018","journal-title":"Bone Marrow Transplant."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/10428194.2020.1827248","article-title":"Evaluation of six different types of sequential conditioning regimens for allogeneic stem cell transplantation in relapsed\/refractory acute myelogenous leukemia\u2014A study of the Acute Leukemia Working Party of the EBMT","volume":"62","author":"Heinicke","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00277-016-2887-4","article-title":"Similar outcome after allogeneic stem cell transplantation with a modified FLAMSA conditioning protocol substituting 4 Gy TBI with treosulfan in an elderly population with high-risk AML","volume":"96","author":"Holtick","year":"2017","journal-title":"Ann. Hematol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/bjh.14428","article-title":"Sequential chemotherapy followed by reduced-intensity conditioning and allogeneic haematopoietic stem cell transplantation in adult patients with relapse or refractory acute myeloid leukaemia: A survey from the Acute Leukaemia Working Party of EBMT","volume":"176","author":"Labopin","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1177\/2040620711402533","article-title":"Salvage therapy for relapsed or refractory acute myeloid leukemia","volume":"2","author":"Mangan","year":"2011","journal-title":"Ther. Adv. Hematol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1200\/JCO.20.03736","article-title":"Venetoclax Combined with FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia","volume":"39","author":"DiNardo","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1016\/j.bbmt.2020.07.020","article-title":"FLAMSA-Based Reduced-Intensity Conditioning versus Myeloablative Conditioning in Younger Patients with Relapsed\/Refractory Acute Myeloid Leukemia with Active Disease at the Time of Allogeneic Stem Cell Transplantation: An Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"26","author":"Labopin","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/ajh.25004","article-title":"Similar outcome of allogeneic stem cell transplantation after myeloablative and sequential conditioning regimen in patients with refractory or relapsed acute myeloid leukemia: A study from the Soci\u00e9t\u00e9 Francophone de Greffe de Moelle et de Th\u00e9rapie Cellulaire","volume":"93","author":"Decroocq","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13045-019-0727-4","article-title":"Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)","volume":"12","author":"Saraceni","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Schulz, F., J\u00e4ger, P., Tischer, J., Fraccaroli, A., Bug, G., Hausmann, A., Baermann, B.N., Tressin, P., Hoelscher, A., and Kasprzak, A. (2024). Smart Conditioning with Venetoclax-Enhanced Sequential FLAMSA + RIC in Patients with High-Risk Myeloid Malignancies. Cancers, 16.","DOI":"10.3390\/cancers16030532"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1038\/leu.2015.37","article-title":"HLA-matched allogeneic stem cell transplantation improves outcome of higher risk myelodysplastic syndrome A prospective study on behalf of SFGM-TC and GFM","volume":"29","author":"Robin","year":"2015","journal-title":"Leukemia"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.bbmt.2014.05.010","article-title":"Upfront allogeneic stem cell transplantation after reduced-intensity\/nonmyeloablative conditioning for patients with myelodysplastic syndrome: A study by the Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Moelle et de Th\u00e9rapie Cellulaire","volume":"20","author":"Damaj","year":"2014","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/bmt.2009.134","article-title":"5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation","volume":"45","author":"Field","year":"2010","journal-title":"Bone Marrow Transplant."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.bbmt.2016.05.026","article-title":"Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A Study of the Myelodysplastic Syndrome Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplant Research","volume":"22","author":"Potter","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1182\/blood-2005-11-4503","article-title":"Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes","volume":"108","author":"Martino","year":"2006","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/bmt.2012.236","article-title":"Comparison of conditioning regimens of various intensities for allogeneic hematopoietic SCT using HLA-identical sibling donors in AML and MDS with <10% BM blasts: A report from EBMT","volume":"48","author":"Martino","year":"2013","journal-title":"Bone Marrow Transplant."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/bmt.2011.69","article-title":"Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS","volume":"47","author":"Luger","year":"2012","journal-title":"Bone Marrow Transplant."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.bbmt.2018.02.007","article-title":"Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience","volume":"24","author":"Alzahrani","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41409-023-02111-3","article-title":"Sequential vs myeloablative vs reduced intensity conditioning for patients with myelodysplastic syndromes with an excess of blasts at time of allogeneic haematopoietic cell transplantation: A retrospective study by the chronic malignancies working party of the EBMT","volume":"59","author":"Potter","year":"2024","journal-title":"Bone Marrow Transplant."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.clml.2021.07.027","article-title":"On Behalf of the SFGM-TC: Retrospective Comparison of Reduced and Higher Intensity Conditioning for High-Risk Myelodysplastic Syndrome Treated with Allogeneic Stem-Cell Transplantation","volume":"22","author":"Campidelli","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"107405","DOI":"10.1016\/j.leukres.2023.107405","article-title":"A new sequential conditioning regimen based on CPX-351\/Vyxeos (\u201cVyx-Seq\u201d) in patients with higher risk myelodysplastic syndromes","volume":"135","author":"Notarantonio","year":"2023","journal-title":"Leuk. Res."},{"key":"ref_53","first-page":"453","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"115","author":"Wei","year":"2022","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1038\/s41375-024-02318-3","article-title":"How risky is a second allogeneic stem cell transplantation?","volume":"38","author":"Penack","year":"2024","journal-title":"Leukemia"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1182\/blood-2018-99-109762","article-title":"A Phase 1 First-in-Human Study of AMG 330, an Anti-CD33 Bispecific T-Cell Engager (BiTE\u00ae) Antibody Construct, in Relapsed\/Refractory Acute Myeloid Leukemia (R\/R AML)","volume":"132","author":"Ravandi","year":"2018","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/blood-2023-179115","article-title":"STING activation improves T-cell-engaging immunotherapy for acute myeloid leukemia","volume":"142","author":"Linder","year":"2023","journal-title":"Blood"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Zhao, Y.L., Liu, D.Y., Sun, R.J., Zhang, J.P., Zhou, J.R., Wei, Z.J., Xiong, M., Cao, X.Y., Lu, Y., and Yang, J.F. (2021). Integrating CAR T-Cell Therapy and Transplantation: Comparisons of Safety and Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation After CAR T-Cell or Chemotherapy-Based Complete Remission in B-Cell Acute Lymphoblastic Leukemia. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.605766"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: What we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1186\/s12967-024-05705-7","article-title":"Efficacy and safety of CAR-T therapy targeting CLL1 in patients with extramedullary diseases of acute myeloid leukemia","volume":"22","author":"Zhao","year":"2024","journal-title":"J. Transl. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood.2024024861","article-title":"Nanobody-based naturally selected CD7-targeted CAR-T therapy for acute myeloid leukemia","volume":"145","author":"Lu","year":"2025","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1056\/NEJMoa2313812","article-title":"Sequential CD7 CAR T-cell therapy and allogeneic HSCT without GVHD prophylaxis","volume":"390","author":"Hu","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1200\/JCO.23.02018","article-title":"Randomized Phase III SIERRA Trial of 131I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed\/Refractory AML","volume":"43","author":"Gyurkocza","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1182\/blood-2003-01-0255","article-title":"Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation","volume":"102","author":"Wadleigh","year":"2003","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1038\/s41409-020-01207-4","article-title":"Outcomes following hematopoietic stem cell transplantation in patients treated with standard chemotherapy with or without gemtuzumab ozogamicin for acute myeloid leukemia","volume":"56","author":"Pautas","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.bbmt.2019.12.763","article-title":"Prior Gemtuzumab Ozogamicin Exposure in Adults with Acute Myeloid Leukemia Does Not Increase Hepatic Veno-Occlusive Disease Risk after Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis","volume":"26","author":"Ho","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e22064","DOI":"10.1097\/MD.0000000000022064","article-title":"Gemtuzumab ozogamicin monotherapy prior to stem cell infusion induces sustained remission in a relapsed acute myeloid leukemia patient after allogeneic stem cell transplantation: A case report","volume":"99","author":"Sumiyoshi","year":"2020","journal-title":"Medicine"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"104746","DOI":"10.1016\/j.exphem.2025.104746","article-title":"Preconditioning intervention prior to allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia","volume":"144","author":"Tachibana","year":"2025","journal-title":"Exp. Hematol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/bjh.19552","article-title":"Early blast clearance during sequential conditioning prior to allogeneic stem cell transplantation in patients with acute myeloid leukaemia","volume":"205","author":"Ronnacker","year":"2024","journal-title":"Br. J. Haematol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1007\/s00277-019-03714-x","article-title":"Risk factors predicting graft-versus-host disease and relapse-free survival after allogeneic hematopoietic stem cell transplantation in relapsed or refractory non-Hodgkin\u2019s lymphoma","volume":"98","author":"Jeon","year":"2019","journal-title":"Ann. Hematol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1182\/blood-2006-07-034348","article-title":"Hyperacute GVHD: Risk factors, outcomes, and clinical implications","volume":"109","author":"Saliba","year":"2007","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1182\/blood.V98.10.2942","article-title":"Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO)","volume":"98","author":"Bacigalupo","year":"2001","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/bjh.15131","article-title":"Anti-thymocyte globulin for graft-versus-host disease prophylaxis in patients with intermediate- or high-risk acute myeloid leukaemia undergoing reduced-intensity conditioning allogeneic stem cell transplantation in first complete remission\u2014A survey on behalf of the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"184","author":"Ofran","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3324\/haematol.2016.148510","article-title":"Anti-thymocyte globulin as graft- versus -host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: A review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"102","author":"Baron","year":"2016","journal-title":"Haematologica"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/j.bbmt.2017.07.007","article-title":"Donor Lymphocyte Infusions Used to Treat Mixed-Chimeric and High-Risk Patient Populations in the Relapsed and Nonrelapsed Settings after Allogeneic Transplantation for Hematologic Malignancies Are Associated with High Five-Year Survival if Persistent Full Donor Chimerism Is Obtained or Maintained","volume":"23","author":"Caldemeyer","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41409-021-01515-3","article-title":"Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia","volume":"57","author":"Schmid","year":"2022","journal-title":"Bone Marrow Transplant."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/s41409-024-02458-1","article-title":"Utility of the 2024 best practice recommendations from the EBMT Cellular Therapy and Immunobiology Working Party for use of donor lymphocyte infusions after allogeneic hematopoietic stem cell transplantation","volume":"60","author":"Mamez","year":"2024","journal-title":"Bone Marrow Transplant."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e70088","DOI":"10.1002\/hem3.70088","article-title":"HLA evolutionary divergence score after donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation","volume":"9","author":"Villemonteix","year":"2025","journal-title":"Hemasphere"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/4\/196\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:03:45Z","timestamp":1760029425000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/4\/196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,27]]},"references-count":78,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["curroncol32040196"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32040196","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,27]]}}}